At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
Tacrolimus +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
In Brief
A Phase 2 clinical trial evaluating PPM-based Computation Assisted Drug Dosing and Tacrolimus for Liver Transplant and Kidney Transplant. Completed, enrolled 62 participants across 3 sites in 2 countries.
Detailed Summary
Clinical trial applying Phenotypic Precision Medicine (PPM) to tacrolimus dosing in liver and/or kidney transplant recipients to show improvement in maintaining drug trough levels within the target range.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Transplant, Kidney Transplant
CountriesSingapore, United States
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartSep 2018
Primary CompletionJun 2020
Study CompletionAug 2021
TodayJul 2026
First PostedMay 17, 2018
Enrollment StartSep 21, 2018
Primary CompletionJun 2, 2020
Study CompletionAug 31, 2021
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.1 years ago
Interventions
PPM-based Computation Assisted Drug Dosingother
Tacrolimus dosing based on application of PPM.
Tacrolimusdrug
Dosing of calcineurin inhibitor, tacrolimus